OpGen Submits Updated 510(k) Summary to FDA and Successfully Completes Move to New Headquarters in Maryland

NEXT STORY
Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’s Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
PREV STORY
AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, challenging treatment standards for people with blood disorders

author_avatar
NASDAQ Market News

Adaptive Biotechnologies to Present New SARS-CoV-2 Data from its Immune Medicine Platform During IDWeek 2021

author_avatar
NASDAQ Market News

HOOKIPA Pharma Reports Second Quarter 2019 Financial Results and Clinical Progress Highlights

author_avatar
NASDAQ Market News